Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Two-Part, Single-Center, Open-Label, Randomized, Cross Over, Single Ascending Doses (SAD), followed by a Multiple Ascending Doses (MAD) Safety and Pharmacokinetic Study of RT234 in Healthy Subjects

Next Previous
Search
Trial Profile

A Phase I, Two-Part, Single-Center, Open-Label, Randomized, Cross Over, Single Ascending Doses (SAD), followed by a Multiple Ascending Doses (MAD) Safety and Pharmacokinetic Study of RT234 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vardenafil (Primary) ; Vardenafil
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Respira Therapeutics

    • Most Recent Events

    • 19 Oct 2020 According to a Respira Therapeutics media release, data from the study will be presented at the American College of Chest Physicians virtual CHEST Annual Meeting 2020. Highlights of the clinical presentation and full data presented at the CHEST Annual Meeting 2020 are available on the Respira website.
    • 16 Oct 2020 Results presented in a Respira Therapeutics media release.
    • 19 Dec 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top